Patents Assigned to Orion Corporation
  • Derivatives of naphthalene with COMT inhibiting activity
    Patent number: 6903114
    Abstract: Compounds of formula (I?), wherein A, R1 to R3 and t are as defined in the disclosure, exhibit COMT enzyme inhibiting activity so that they are useful as COMT inhibitors.
    Type: Grant
    Filed: September 14, 2001
    Date of Patent: June 7, 2005
    Assignee: Orion Corporation
    Inventors: Reijo Bäckström, Jarmo Pystynen, Timo Lotta, Martti Ovaska, Jyrki Taskinen
  • Moisture protected powder inhaler
    Patent number: 6886560
    Abstract: A powder inhaler comprising a powder container, an air channel, a metering member equipped with a dosing recess, an actuating means for the displacement of the metering member between the filling and the inhalation position, and a closure element for plugging the air channel in a substantially water-proof manner when the metering member is in the filling position and opening the air channel when the metering member is in the inhalation position. When the inhaler is not in use, the closure element prevents moisture and dirt from entering the sensitive parts of the device.
    Type: Grant
    Filed: September 15, 2000
    Date of Patent: May 3, 2005
    Assignee: Orion Corporation
    Inventor: Kari Seppälä
  • Soluble compositions of triphenylethylene antiestrogens
    Patent number: 6887888
    Abstract: Aqueous compositions of nonsteroidal triphenylethylene antiestrogens for pharmaceutical use comprising as a solubility enhancing agent a pharmaceutically acceptable mono- or dicarboxylic acid having 1-5 carbon atoms, wherein the carbon chain may further contain 1-4 hydroxyl, 1-3 oxo, or one or several halogen substituents, or a corresponding anion thereof, or methanesulfonic acid or its corresponding anion, in molar excess with respect to the triphenylethylene antiestrogen, optionally together with an organic water miscible co-solvent such as polyethylene glycol (PEG), propylene glycol, ethanol or isopropanol.
    Type: Grant
    Filed: April 8, 2003
    Date of Patent: May 3, 2005
    Assignee: Orion Corporation
    Inventors: Kaija AF Ursin, Jukka Salmia, Heikki Niskanen, Pirjo Kortesuo, Mikko Kananen, Gunilla Örn, Juha Kiesvaara
  • Anti-inflammatory agents
    Patent number: 6878702
    Abstract: The use of mitochondrial KATP channel openers, particularly compounds of general formula (I), for the treatment or prevention of inflammation by inducing apoptosis of inflammatory cells.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: April 12, 2005
    Assignee: Orion Corporation
    Inventors: Heimo Haikala, Minja Hyttilä-Hopponen, Erkki Nissinen, Minna Ruotsalainen, Aino Pippuri, Kari Lönnberg
  • Treatment of osteoporosis
    Patent number: 6846496
    Abstract: A method for the prevention or treatment of postmenopausal osteoporosis by initiating the treatment with a low close of an estrogenic compound and increasing the dose of the estrogenic compound after the initiation period.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: January 25, 2005
    Assignee: Orion Corporation
    Inventors: Ulla Timonen, Raija Vaheri
  • Powder inhaler
    Patent number: 6814072
    Abstract: A device for dispensing powdered medicament by inhalation comprises an axially movable metering rod (3) equipped with a dosing recess in the form of a hole (5). The metering rod (3) extends through the interior of the medicament container (1). In a first position the dosing hole (5) is in the medicament container (1) and is filled with a dose of the powdered medicament. In the second position the filled dosing hole (5) is in the air channel (11). The device of the invention has good metering accuracy, it is not susceptible to jamming and provides complete discharge of the powdered dose into the breathing air even if used by a patient having reduced inhalation capacity.
    Type: Grant
    Filed: January 16, 2002
    Date of Patent: November 9, 2004
    Assignee: Orion Corporation
    Inventor: Kari Seppälä
  • Pharmaceutical composition comprising entracapone, levodopa, and carbidopa
    Patent number: 6797732
    Abstract: An oral solid fixed dose composition comprising pharmacologically effective amounts of entacapone, levodopa, and carbidopa, or pharmaceutically acceptable salts or hydrates thereof, and comprising at least one pharmaceutically acceptable excipient. The composition can be used, e.g., for the treatment of Parkinson's disease.
    Type: Grant
    Filed: August 20, 2002
    Date of Patent: September 28, 2004
    Assignee: Orion Corporation
    Inventors: Matti Virkki, Kari Vahervuo, Marja Ritala, Marja Partanen, Mervi Niskanen, Jarmo Lintulaakso, Marja Laaksonen, Lasse Kervinen, Sari Kallioinen
  • Compounds for deactivating phospholamban function on Ca-ATPase (phospholamban inhibitors)
    Patent number: 6774103
    Abstract: This invention relates to determining the three-dimensional structure of the cytosolic domain of phospholamban (PLB) and its active site from NMR data of sufficiently high resolution for the three-dimensional structure determination. The invention also relates to methods for rational drug design enabling the design of phospholamban inhibitors based on using the three-dimensional structure data provided on computer readable media, as analyzed on a computer system having suitable computer algorithms. The invention also relates to phospholamban inhibiting compounds with certain structural, physicochemical and spatial characteristics that allow for the interaction of said compounds with specific residues of the active site of phospholamban.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: August 10, 2004
    Assignee: Orion Corporation
    Inventors: Piero Pollesello, Martti Ovaska, Jukka Tenhunen, Jukka Vidgren, Marjo Yliperttula-Ikonen, Carola Tilgmann, Timo Lotta, Juha Kaivola
  • Inhaler with a dose counter
    Patent number: 6769601
    Abstract: A multiple-dose powder inhaler comprising an inhaler body defining a medicament container, an air channel, a mouthpiece, a rotatable metering drum with one or more peripheral dosing recesses and a dose counter for indicating the number of metered doses of medicament that have been dispensed from, or remain in, the medicament container. The inhaler is useful, for example, in the treatment of asthma.
    Type: Grant
    Filed: July 16, 2003
    Date of Patent: August 3, 2004
    Assignee: Orion Corporation
    Inventors: Jussi Haikarainen, Kari Seppälä, Jarkko Munukka, Esa Muttonen, Elizabeth Stares, Martin Murphy, Matthew Young
  • Process for the preparation of 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
    Patent number: 6753433
    Abstract: Method for the preparation of 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile (citalopram) comprising the reaction of a compound of formula wherein X is a halogen, with organometallic dimethylaminopropyl halide. Other aspects of the invention are new compounds of formula II and formula III and their preparation.
    Type: Grant
    Filed: February 24, 2003
    Date of Patent: June 22, 2004
    Assignee: Orion Corporation, FERMION
    Inventors: Leif Hilden, Tuomas Huuhtanen, Petteri Rummakko, Arne Grumann, Pekka Pietikaeinen
  • Pharmaceutical solutions of levosimendan
    Publication number: 20040106617
    Abstract: Levosimendan solutions for pharmaceutical use, and particularly for intravenous administration. The solutions of the invention have enhanced stability and they are particularly useful as infusion or injection solutions or infusion concentrates. Levosimendan is useful in the treatment of congestive heart failure.
    Type: Application
    Filed: November 10, 2003
    Publication date: June 3, 2004
    Applicant: Orion Corporation
    Inventors: Reijo Backstrom, Paivi Granvik, Ritva Haikala, Sirpa Pelttari, Eva Saukko, Reija Yrjola
  • Pharmaceutical solutions of levosimendan
    Patent number: 6730673
    Abstract: Levosimendan solutions for pharmaceutical use, and particularly for intravenous administration. The solutions of the invention have enhanced stability and they are particularly useful as infusion or injection solutions or infusion concentrates. Levosimendan is useful in the treatment of congestive heart failure.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: May 4, 2004
    Assignee: Orion Corporation
    Inventors: Reijo Bäckström, Päivi Granvik, Ritva Haikala, Sirpa Pelttari, Eva Saukko, Reija Yrjölä
  • Use of COMT inhibitors as analgesics
    Patent number: 6723754
    Abstract: The use of COMT inhibitors in the treatment of control of pain in mammals, for example in animals and humans.
    Type: Grant
    Filed: September 13, 2002
    Date of Patent: April 20, 2004
    Assignee: Orion Corporation
    Inventors: Päivi Aho, Inge-Britt Lindén
  • Method for preparing sertraline
    Patent number: 6723878
    Abstract: (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine (sertraline) may be prepared by hydrogenating of N-[4-(3,4-dichlorophenyl)-3, 4-dihydro-1(2H)-naphthalenylidene]methanamine in the presence of a dehalogenation inhibitor, e.g., triphenylphosphite or trimethylphosphite and a catalyst.
    Type: Grant
    Filed: June 14, 2002
    Date of Patent: April 20, 2004
    Assignee: Orion Corporation Fermion
    Inventor: Ilpo Laitinen
  • Use of dexmedetomidine for ICU sedation
    Patent number: 6716867
    Abstract: The present invention relates to a method of sedating a patient while in the intensive care unit comprising administering dexmedetomidine of a pharmaceutically acceptable salt thereof to the patient, wherein the patient remains arousable and orientated.
    Type: Grant
    Filed: December 6, 2000
    Date of Patent: April 6, 2004
    Assignee: Orion Corporation
    Inventors: Riku Aantaa, Romeo Bachand, Esa Heinonen
  • Pyridazinyl phenyl hydrazones useful against congestive heart failure
    Patent number: 6699868
    Abstract: Therapeutically active compounds of formula (I): in which R1 to R4 means hydrogen, alkyl, alkenyl, aryl, arylalkyl, carboxyalkyl, hydroxyalkyl or halogenalkyl, or R2 and R3 form a ring of 5-7 carbon atoms, R5 to R9 means hydrogen, alkyl, alkenyl, aryl, arylalkyl, acyl, hydroxy, alkoxy, alkoxycarbonyl, amino, acylamino, alkylamino, aryloxy, halogen, cyano, nitro, carboxy, alkylsufonyl, sulfonamido or trifluoromethyl, wherein each aryl residue defined above by itself or as a part of another group may be substituted, and pharmaceutically acceptable salts and esters thereof. The compounds increase the calcium sensitivity of contractile proteins of the cardiac muscle and are thus useful in the treatment of congestive heart failure.
    Type: Grant
    Filed: December 26, 2002
    Date of Patent: March 2, 2004
    Assignee: Orion Corporation
    Inventors: Jarmo Pystynen, Aino Pippuri, Anne Luiro, Pentti Nore, Reijo Bäckström, Kari Lönnberg, Heimo Haikala, Jouko Levijoki, Petri Kaheinen, Juha Kaivola
  • Derivatives of quinoline as alpha-2 antagonists
    Publication number: 20030225078
    Abstract: A compound of formula I, 1
    Type: Application
    Filed: April 16, 2003
    Publication date: December 4, 2003
    Applicants: Orion Corporation, Oy Juvantia Pharma Ltd.
    Inventors: Siegfried Wurster, Mia Engstrom, Juha-Matti Savola, Iisa Hoglund, Jukka Sallinen, Antti Haapalinna, Andrei Yurievitch Tauber, Anna-Marja Katariina Hoffren, Harri Elias Salo
  • Soluble compositions of triphenylethylene antiestrogens
    Patent number: 6632841
    Abstract: Aqueous compositions of nonsteroidal triphenylethylene antiestrogens for pharmaceutical use comprising as a solubility enhancing agent a pharmaceutically acceptable mono- or dicarboxylic acid having 1-5 carbon atoms, wherein the carbon chain may further contain 1-4 hydroxyl, 1-3 oxo, or one or several halogen a substituents, or a corresponding anion thereof, or methanesulfonic acid or its corresponding anion, in molar excess with respect to the triphenylethylene antiestrogen, optionally together with an organic water miscible co-solvent such as polyethylene glycol (PEG), propylene glycol, ethanol or isopropanol.
    Type: Grant
    Filed: October 2, 2001
    Date of Patent: October 14, 2003
    Assignee: Orion Corporation
    Inventors: Kaija Af Ursin, Jukka Salmia, Heikki Niskanen, Pirjo Kortesuo, Mikko Kananen, Gunilla Örn, Juha Kiesvaara
  • Soluble compositions of triphenylethylene antiestrogens
    Publication number: 20030181530
    Abstract: The invention relates to aqueous compositions of nonsteroidal triphenylethylene antiestrogens for pharmaceutical use comprising as a solubility enhancing agent a pharmaceutically acceptable mono- or dicarboxylic acid having 1-5 carbon atoms, wherein the carbon chain may further contain 1-4 hydroxyl, 1-3 oxo, or one or several halogen substituents, or a corresponding anion thereof, or methanesulfonic acid or its corresponding anion, in molar excess with respect to the triphenylethylene antiestrogen, optionally together with an organic water miscible co-solvent such as polyethylene glycol (PEG), propylene glycol, ethanol or isopropanol.
    Type: Application
    Filed: April 8, 2003
    Publication date: September 25, 2003
    Applicant: Orion Corporation
    Inventors: Kaija Af Ursin, Jukka Salmia, Heikki Niskanen, Pirjo Kortesuo, Mikko Kananen, Gunilla Orn, Juha Kiesvaara
  • HIGH PURITY (1R,2S,4R)-(?)-2-[(2?-{N,N-DIMETHYLAMINO}-ETHOXY)]-2-[PHENYL]-1,7,7 -TRI-[METHYL]-BICYCLO [2.2.1]HEPTANE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF AND A PROCESS FOR THE PREPARATION OF THESE COMPOUNDS AS WELL AS MEDICAMENTS CONTAINING 1 OR MORE OF THESE COMPOUNDS AND THEIR USE
    Patent number: 6624201
    Abstract: The invention relates to high purity (1R,2S,4R)-(−)-2-[(2′-{N,N-dimethylamino}-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof containing not more than 0.2% of (1R,3S,4R)-3-[(2′-{N,N-dimethylamino}-ethyl)]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane-2-one and/or of a pharmaceutically acceptable acid addition salt thereof. Furthermore the invention is concerned with a process for the preparation of these compounds. Moreover the invention relates to medicaments containing 1 or more of these compounds and their use.
    Type: Grant
    Filed: October 30, 2001
    Date of Patent: September 23, 2003
    Assignee: Orion Corporation
    Inventors: Gyula Lukács, Gyula Simig, Tibor Mezei, Zoltán Budai, Márta Porcs-Makkay, György Krasznai, Kálmán Nagy, Györgyi Donáth Vereczkey, Tibor Szabó, Norbert Németh, János Szulágyi